COMITO, FRANCESCA
COMITO, FRANCESCA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
Defining high-risk patients: beyond the 8the AJCC melanoma staging system
2025 Broseghini, E.; Veronesi, G.; Gardini, A.; Venturi, F.; Scotti, B.; Vespi, L.; Marchese, P. V.; Melotti, B.; Comito, F.; Corti, B.; Ferracin, M.; Dika, E.
A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management
2024 Casadio, C.; Galvani, L.; De Giglio, A.; Casadei, C.; Tardio, M.L.; Melotti, B.; Sperandi, F.; Gelsomino, F.; Comito, F.
Analysis of basal cell carcinomas' histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin–Goltz syndrome: A retrospective study
2023 Scotti B.; Melotti B.; Baraldi C.; Comito F.; Venturi F.; Lambertini M.; Dika E.
Cemiplimab-Induced alopecia areata
2023 Piraccini, B. M.; Comito, F.; Melotti, B.; Stanganelli, I.; Medri, M.; Savoia, F.
Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: A newly described occurrence
2023 Lambertini M.; Comito F.; Melotti B.; Baracca M.F.; Dika E.
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
2023 Rossi, Simone; Cani, Ilaria; Raschi, Emanuel; Comito, Francesca; Rinaldi, Rita; Ardizzoni, Andrea; Guarino, Maria; Gelsomino, Francesco
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
2023 Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M.
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY
2023 Raschi E.; Comito F.; Massari F.; Gelsomino F.
Retreatment with sonidegib in a patient with multiple basal cell carcinomas and multiple comorbidities: a complex real-life scenario
2023 Comito, Francesca; Gagliano, Ambrogio; Sperandi, Francesca; Dika, Emi; Savoia, Francesco; Melotti, Barbara
Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer
2022 Durante G.; Broseghini E.; Comito F.; Naddeo M.; Milani M.; Salamon I.; Campione E.; Dika E.; Ferracin M.
Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: A single-institution experience
2022 Comito F.; Aprile M.; Pagani R.; Siepe G.; Sperandi F.; Gruppioni E.; Altimari A.; De Biase D.; Melotti B.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
2022 Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R.
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
2022 Comito, Francesca; Pagani, Rachele; Grilli, Giada; Sperandi, Francesca; Ardizzoni, Andrea; Melotti, Barbara
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab
2021 Comito F.; Nigro M.C.; Sperandi F.; Melotti B.; Ardizzoni A.
Non-coding RNA dysregulation in skin cancers
2021 Durante G.; Comito F.; Lambertini M.; Broseghini E.; Dika E.; Ferracin M.
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience
2020 Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F.
Circulating tumor cells in genitourinary tumors
2018 Massari, Francesco*; Di Nunno, Vincenzo; Comito, Francesca; Cubelli, Marta; Ciccarese, Chiara; Iacovelli, Roberto; Fiorentino, Michelangelo; Montironi, Rodolfo; Ardizzoni, Andrea
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study
2018 Bersanelli M.; Giannarelli D.; Castrignano P.; Fornarini G.; Panni S.; Mazzoni F.; Tiseo M.; Rossetti S.; Gambale E.; Rossi E.; Papa A.; Cortellini A.; Lolli C.; Ratta R.; Michiara M.; Milella M.; Luca E.D.; Soraru M.; Mucciarini C.; Atzori F.; Banna G.L.; Torre L.L.; Vitale M.G.; Massari F.; Rebuzzi S.E.; Facchini G.; Schinzari G.; Tomao S.; Bui S.; Vaccaro V.; Procopio G.; Giorgi U.D.; Santoni M.; Ficorella C.; Sabbatini R.; Maestri A.; Natoli C.; Tursi M.D.; Maio M.D.; Rapacchi E.; Pireddu A.; Sava T.; Lipari H.; Comito F.; Verzoni E.; Leonardi F.; Buti S.
Mutational burden of resectable pancreatic cancer by whole-transcriptome and whole-exome sequencing could predict a poor prognosis
2018 Grassi, Elisa; Durante, Sandra; Astolfi, Annalisa; Tarantino, Giuseppe; Indio, Valentina; Freier, Eva; Casadei, Riccardo; Ricci, Claudio; Comito, Francesca; Filippini, Daria; Formica, Francesca; Serra, Carla; Santini, Donatella; D'Errico, Antonietta; Minni, Francesco; Biasco, Guido; Di Marco, Mariacristina
Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis.
2018 Grassi E, Durante S, Astolfi A, Tarantino G, Indio V, Freier E, Vecchiarelli S, Ricci C, Casadei R, Formica F, Filippini D, Comito F, Serra C, Santini D, D' Errico A, Minni F, Biasco G, Di Marco M